The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

The present disclosure relates a method of fabricating a literal flow immunoassay (LFIA) for the diagnosis of diseases, including COVID-19. The present disclosure further relates to a fusion-epitopes peptide that can be used in the LFIA test to improve sensitivity, specificity and accuracy of the test.

The present invention relates to a composition comprising a solid carrier, a capture moiety, a functional protein, a first linker connecting the capture moiety to the solid carrier, a second linker connecting the functional protein to the capture moiety, a first protective layer fully embedding the solid carrier, fully or partially embedding the first linker, and not or partially embedding the capture moiety, a second protective layer fully or partially embedding the capture moiety, fully embedding the second linker, and fully or partially embedding the functional protein.

The present invention generally relates to improved pharmacokinetic assays for measuring levels of immunoglobulin single variable domains (also referred to herein as ISVs or ISVDs) and of proteins and polypeptides that comprise at least one ISV (as further described herein) in biological samples.

The present invention generally relates to improved pharmacokinetic assays for measuring levels of immunoglobulin single variable domains (also referred to herein as ISVs or ISVDs) and of proteins and polypeptides that comprise at least one ISV (as further described herein) in biological samples.

The present invention provides an assay device for detecting an analyte in a fluid sample, comprising: a sample receiving member (1), which is fluidically connected to at least two components (2, 3) defining an assay flow path, at least one of which is a detection member (3) comprising an analyte detection zone (31); and a sample detection element (13) adapted to detect fluid at a particular point along the assay flow path. The present invention also provides the use of the assay device of the invention for indicating sample sufficiency when the assay device is exposed to a fluid sample and for indicating to a user after sampling that the device has failed due to insufficient sampling, and a method of alerting a user to the fact that a sufficient sample has been applied to an assay device of the invention.

The present invention provides an assay device for detecting an analyte in a fluid sample, comprising: a sample receiving member (1), which is fluidically connected to at least two components (2, 3) defining an assay flow path, at least one of which is a detection member (3) comprising an analyte detection zone (31); and a sample detection element (13) adapted to detect fluid at a particular point along the assay flow path. The present invention also provides the use of the assay device of the invention for indicating sample sufficiency when the assay device is exposed to a fluid sample and for indicating to a user after sampling that the device has failed due to insufficient sampling, and a method of alerting a user to the fact that a sufficient sample has been applied to an assay device of the invention.

The present disclosure provides all-in-one cartridges which contain necessary reagents and materials to isolate/preconcentrate targeted proteins from blood plasma and ionize them for mass spectrometry detection. In another configuration, the cartridges include proteolytic enzymes to digest the proteins into smaller peptides in addition to preconcentration and ionization for mass spectrometry detection.

The present disclosure relates to a nanostructure for detecting viruses including an amphipathic polymer, and a diagnostic platform using the same, wherein the nanostructure is capable of specifically detecting viruses through silica-based nanoparticles with excellent stability and high dispersion and a biocompatible amphipathic polymer, such that it is possible to develop a diagnostic platform with high sensitivity through binding and agglomeration of the nanostructure and viruses and enable rapid and accurate diagnosis of a target virus.